281 related articles for article (PubMed ID: 8623492)
1. FK 506 induction and rescue therapy in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Castaldo P; Sindhi R; Sudan D; Weide LG; Frisbie K; Cushing KA; Jerius J; Radio SJ
Transplant Proc; 1996 Apr; 28(2):991-2. PubMed ID: 8623492
[No Abstract] [Full Text] [Related]
2. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
3. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation.
Ketel BL; Turton-Weeks S; Reed K; Barone GW
Transplant Proc; 1996 Apr; 28(2):899. PubMed ID: 8623453
[No Abstract] [Full Text] [Related]
4. FK 506-based immunosuppression in clinical pancreas transplantation.
Swanson C; Rubin M; Colquhoun S; Basadonna G; Asshinnik A; Perez R
Transplant Proc; 1995 Dec; 27(6):3031. PubMed ID: 8539827
[No Abstract] [Full Text] [Related]
5. Cyclosporine therapy in pancreas transplantation.
Davidson I; Lu C; Melone D; Risser R
Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
[No Abstract] [Full Text] [Related]
6. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
7. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
[No Abstract] [Full Text] [Related]
8. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
9. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
Schulz T; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475
[TBL] [Abstract][Full Text] [Related]
10. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
[No Abstract] [Full Text] [Related]
11. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial.
Land W; Malaise J; Sandberg J; Langrehr J;
Transplant Proc; 2002 Aug; 34(5):1911-2. PubMed ID: 12176625
[No Abstract] [Full Text] [Related]
12. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
13. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
14. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy.
Kaufman DB; Leventhal JR; Stuart J; Parker M; Abecassis M; Fryer JP; Stuart FP
Transplant Proc; 1999; 31(1-2):615-6. PubMed ID: 10083261
[No Abstract] [Full Text] [Related]
15. Incidence and impact of acute rejection episodes on short- and long-term graft survival in recipients of simultaneous pancreas-kidney transplantation.
Cantarovich D; Giral M; Josien R; Karam G; Hourmant M; Dantal J; Blancho G; Soulillou JP
Transplant Proc; 1995 Feb; 27(1):1319. PubMed ID: 7878897
[No Abstract] [Full Text] [Related]
16. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
el-Ghoroury M; Hariharan S; Peddi VR; Munda R; Schroeder TJ; Demmy AM; Alexander JW; First MR
Transplant Proc; 1997; 29(1-2):649-51. PubMed ID: 9123461
[No Abstract] [Full Text] [Related]
18. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
19. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
[No Abstract] [Full Text] [Related]
20. Cyclosporin monotherapy in pancreaticorenal transplantation.
Ward RG; Gecim E; Bone JM; Bakran A; Sells RA
Transplant Proc; 1994 Apr; 26(2):548. PubMed ID: 8171547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
